Thymosin Alpha-1: Immune-cell models and their limits

Dendritic cells in the laboratory

A 2007 study examined differentiation and maturation of dendritic cells derived from human CD14-positive monocytes. Measurements included cell characteristics and functional responses in a controlled cell system. [1]

Distinguishing model and organism

An experiment using human cells is not a clinical study in people. An altered cellular response can address a mechanistic question; a health benefit would require separate investigation using suitable clinical outcomes.

The formats offered

Thymosin Alpha-1 is listed as a 10 mg vial and a 10 mg pen. The amount describes total content. For the pre-filled format, volume, solvent and batch documentation must also be considered.

Avoid transferring findings between thymosins

Findings for thymosin alpha-1 cannot be used as evidence for TB-500 simply because the names are similar. The reverse also applies. Identity, sequence and test material need unambiguous identification before comparison.

Sources & context

1. Thymosin-alpha1: human monocyte-derived dendritic cells (2007)

Sources concern the models and preparations investigated, rather than a particular shop batch. Research products are intended exclusively for laboratory research, not for human use.